Gabapentin

Drug Profile

Gabapentin

Alternative Names: CI 945; GOE 3450; Neurontin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Pfizer
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Epilepsy; Neuralgia; Neuropathic pain; Postherpetic neuralgia
  • Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Bipolar disorders; Migraine; Spinal muscular atrophy

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 09 Jun 2010 First generic equivalent approved in USA for Postherpetic neuralgia
  • 26 Jul 2006 Registered for Epilepsy in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top